Skip to content
Screener

Halozyme Therapeutics HALO Payments to Acquire Property, Plant, and Equipment

Payments to Acquire Property, Plant, and Equipment at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$16.08M+30.7%
Amgen logo
AmgenAMGN
$513M+39.0%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
AptarGroup logo
AptarGroupATR

Other financials

Income statement

See full
Revenue$481.0M+47.7%
Gross profit$401.8M+43.8%
Operating income$287.7M+42.1%
Net income$229.9M+39.2%
EPS (diluted)$1.90+42.9%

Balance sheet

See full
Cash & equivalents$164.0M+165%
Total debt$2.2B+41.6%
Total equity$143.5M-56.9%
Total assets$2.6B+25.5%

Cash flow

See full
Operating cash flow$240.9M+142%
CapEx$4.2M+167%
Free cash flow$236.7M+141%

Valuation

See full
Market cap$12.23B+66.3%
Enterprise value$14.25B+61.3%
P/E17×-4.9×
P/S7.4×+1.1×

Profitability

See full
Gross margin82.4%-1.8pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin48.5%+2.6pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity15.2×+10.6×
Current ratio2.7×-5.7×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001159036-26-000104
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Purchases of marketable securities(120,605)(242,399)
Proceeds from sales and maturities of marketable securities62,269239,278
Proceeds from working capital adjustments on acquisition710
Purchases of property and equipment(7,914)(2,513)
Net cash used in investing activities(65,540)(5,634)
Financing activities
Repurchase of common stock(332,729)(303,489)
Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement4,8651,202

Item 1. Financial Statements

FAQ

What is Halozyme Therapeutics's payments to acquire property, plant, and equipment?
Halozyme Therapeutics (HALO) reported payments to acquire property, plant, and equipment of $4.17M in Q2 2026.
How has Halozyme Therapeutics's payments to acquire property, plant, and equipment changed year-over-year?
Halozyme Therapeutics's payments to acquire property, plant, and equipment increased by 167.0% year-over-year, from $1.56M to $4.17M.
What is the long-term trend for Halozyme Therapeutics's payments to acquire property, plant, and equipment?
Over 3 years (2021 to 2025), Halozyme Therapeutics's payments to acquire property, plant, and equipment has grown at a 68.5% compound annual growth rate (CAGR), from $1.46M to $6.97M.
What does payments to acquire property, plant, and equipment mean?
Payments to Acquire Property, Plant, and Equipment

Ask your AI about Halozyme Therapeutics's payments to acquire property, plant, and equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude